Acknowledging  that chlorofluorocarbon consumption and production in Parties operating under paragraph 1 of Article 5 will cease from 1 January 2010, with possible essential-use exemptions,   Acknowledging also  that many Parties operating under paragraph 1 of Article 5 import chlorofluorocarbon-free metered-dose inhalers from Parties not operating under paragraph 1 of Article\xc2\xa05,   Recognizing  that campaign production offers potential advantages in lieu of annual essential\xe2\x80\x91use nominations under decision IV/25 to meet needs for pharmaceutical-grade chlorofluorocarbons,   Noting  that decision XVIII/16, paragraph 12, requested the Technology and Economic Assessment Panel to assess \xe2\x80\x9cquantities for a limited campaign production of chlorofluorocarbons exclusively for metered-dose inhalers in Parties operating under paragraph 1 of Article 5 and Parties not operating under paragraph 1 of Article 5,\xe2\x80\x9d    Noting also  that the Medical Technical Options Committee presented findings concerning the amounts of chlorofluorocarbons that may be needed for metered-dose inhalers only for Parties operating under paragraph 1 of Article 5 in 2008,   Acknowledging  that the Medical Technical Options Committee has reported the need for additional information concerning the operations of a final campaign for Article 5 Parties except from one major manufacturing Party,  1.\xc2\xa0\xc2\xa0 To request that the Technology and Economic Assessment Panel present a report to the Twenty-First Meeting of the Parties, preceded by a preliminary report to the Open-ended Working Group at its twenty-ninth meeting, concerning:     (a)\xc2\xa0 The potential timing for final campaign production, taking into account, among other things, the information submitted in the nominations for 2010 and   that some Parties operating under paragraph 1 of Article 5 may prepare essential use nominations for the first time for the Twenty-First Meeting of the Parties;     (b) Options for long-term storage, distribution, and management of produced quantities of pharmaceutical-grade chlorofluorocarbons before they are needed by Parties, including existing methods used by Parties not operating under paragraph 1 of Article 5;    (c)\xc2\xa0 Options for minimizing the potential for too much or too little chlorofluorocarbons production as part of a final campaign;    (d) Contractual arrangements that may be necessary, considering the models currently used by Parties not operating under paragraph 1 of Article 5 that submit essential\xe2\x80\x91use nominations consistent with decision IV/25;     (e)\xc2\xa0 Options for reducing production of non-pharmaceutical-grade chlorofluorocarbons, together with options for final disposal of such chlorofluorocarbons;      2.\xc2\xa0\xc2\xa0 To request the Multilateral Fund Secretariat to report to the Open\xe2\x80\x91ended Working Group at its twenty-ninth meeting on the status of agreements to convert metered-dose inhaler manufacturing facilities located in Parties operating under paragraph 1 of Article 5 and the implementation of approved projects;